All In Biotech

Drug Trial Radar · NCT00922480

Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients

A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Apr 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 506 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

506

Actual

Start

Dec 2008

Primary completion

Jul 2009

Study completion Sep 2009

Sponsor

Sponsor type
Industry
Collaborators
Seoul National University Hospital; The Catholic University of Korea; Kangbuk Samsung Hospital; Konkuk University Medical Center; Konyang University Hospital; Keimyung University; Korea University; Korea University Guro Hospital; Dongguk University International Hospital; Seoul National University Bundang Hospital; Samsung Medical Center; Asan Medical Center; Severance Hospital; Ajou University; Wonju Severance Christian Hospital; Yeungnam University Hospital; Yonsei University; Inha University Hospital; Chonbuk National University Hospital; Cheil General Hospital and Women's Healthcare Center; Chungnam National University; Chungbuk National University Hospital; Hanyang University
First posted
Jun 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg\~120 mg in patients with mild to moderate essential hypertension.

Conditions

  • Hypertension

Interventions

  • FimasartanDrug

    Fimasartan 60 \~ 120mg/po take one tablets once a day

  • Losartan (Control)Drug

    Losartan 50 mg \~ 100 mg/po, take one tablets once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diastolic Blood Pressure ChangeTime frame: baseline and 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.